Repros in the News
To receive Press Releases via email, Click Here.
07/01/2009 - 06:00 AM
Repros Therapeutics Inc. Provides Update for Proellex® Clinical Program
06/05/2009 - 06:00 AM
Repros Therapeutics Inc. Establishes Scientific Advisory Board
05/11/2009 - 06:00 AM
Repros Therapeutics Inc. Reports First Quarter 2009 Financial Results and Provides Clinical Program Update
04/17/2009 - 06:00 AM
Repros Therapeutics Inc. Board Nominates Dr. Stephen Howell to Its Board of Directors
03/20/2009 - 12:15 PM
Repros Announces 2009 Annual Shareholders' Meeting
03/16/2009 - 06:00 AM
Repros Therapeutics Inc. Reports Fourth Quarter and Year End 2008 Financial Results
03/12/2009 - 04:49 PM
Repros to Report Fourth Quarter and Full Year 2008 Financial Results on March 16, 2009
02/23/2009 - 06:00 AM
Repros Therapeutics Announces Appointment of Dr. Paul Lammers as President
02/03/2009 - 06:00 AM
Repros Presentation to Be Webcast from the 11th Annual Bio/CEO & Investor Conference and the Roth 21st Annual OC Growth Stock Conference
01/27/2009 - 06:00 AM
Repros Therapeutics Inc. Announces Information In Compliance With NASDAQ Marketplace Rule 4350
01/12/2009 - 06:00 AM
Repros Therapeutics Inc. Announces That Proellex Significantly Reduced Pain in a U.S. Phase 2 Clinical Trial in Women with Moderate to Severe Endometriosis
12/22/2008 - 01:15 PM
Repros Therapeutics Inc. Board of Directors Elects Mark Lappe of Efficacy Capital as Its Chairman of the Board
11/10/2008 - 05:10 PM
Repros Therapeutics Inc. Files Shelf Registration
11/10/2008 - 06:00 AM
Repros Therapeutics Inc. Reports Third Quarter 2008 Financial Results
10/29/2008 - 04:24 PM
Repros Presentation to Be Webcast from the Oppenheimer 19th Annual Healthcare Conference, the Rodman & Renshaw 10th Annual Healthcare Conference and the 20th Annual Piper Jaffray Healthcare Conference
10/02/2008 - 07:00 PM
Repros Therapeutics Inc. Announces Closing of Previously Announced Direct Registered Offering
09/29/2008 - 08:45 AM
Repros Therapeutics Inc. Announces $15.6 Million Financing
08/21/2008 - 06:00 AM
Repros Therapeutics Inc. Announces No Tumors in First Completed Proellex Animal Carcinogenicity Study
08/18/2008 - 06:00 AM
Repros Therapeutics Inc. Provides Update for US Phase II Endometriosis Study and Completion of QT Interval Dose Selection Screen
08/11/2008 - 06:00 AM
Repros Therapeutics Inc. Reports Second Quarter 2008 Financial Results
07/21/2008 - 06:00 AM
Repros Therapeutics Inc. Announces That the Results of the European Trial Demonstrating Uterine Fibroid Size Reduction in Patients Administered Proellex(R) Will Be in Print in August 2008
07/18/2008 - 12:30 PM
Repros Therapeutics Inc. Announces That Initial Findings for Proellex(R) Show No Tumorigenic Response in a Two-year Carcinogenicity Study in Rats
07/16/2008 - 05:43 PM
Repros Therapeutics Inc. Announces That Proellex(R) Administered to Patients as Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium
07/14/2008 - 08:00 AM
Repros to Host Analyst Meeting, July 24, 2008
07/11/2008 - 06:00 AM
Repros Therapeutics Inc. Announces That Proellex Significantly Reduces Pain in a U.S. Phase 2 Clinical Trial in Women with Moderate to Severe Endometriosis
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax